Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation

American Journal of Cardiology

Volumn 114, Issue 4, 2014, Pages 646-653

  Providência, Rui ^a,b   Marijon, Eloi ^c   Boveda, Serge ^a   Barra, Sérgio ^d   Narayanan, Kumar ^c,e   Le Heuzey, Jean Yves ^c   Gersh, Bernard J ^f   Gonçalves, Lino ^b  

^a CLINIQUE PASTEUR   (France)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PAPWORTH HOSPITAL   (United Kingdom)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; HEART ATRIUM FIBRILLATION; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS (TOPIC); NONVALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; COMPLICATION; HEALTH; META ANALYSIS; MORBIDITY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; SURVIVAL RATE; TRENDS;

ATRIAL FIBRILLATION; GLOBAL HEALTH; HUMANS; MORBIDITY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL RATE; THROMBOEMBOLISM;

EID: 84906101704     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.05.048     Document Type: Review

References (30)

1. H.J. Lin, P.A. Wolf, M. Kelly-Hayes, A.S. Beiser, C.S. Kase, E.J. Benjamin, and R.B. D'Agostino Stroke severity in atrial fibrillation. The Framingham Study Stroke 27 1996 1760 1764
2. A.S. Go, M.C. Fang, N. Udaltsova, Y. Chang, N.K. Pomernacki, L. Borowsky, D.E. Singer ATRIA Study Investigators Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study Circulation 119 2009 1363 1369
3. M.D. Ezekowitz, S.L. Bridgers, K.E. James, N.H. Carliner, C.L. Colling, C.C. Gornick, H. Krause-Steinrauf, J.F. Kurtzke, S.M. Nazarian, M.J. Radford, F.R. Rickles, R. Shabetai, D. Deykin the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veteran Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators N Engl J Med 327 1992 1406 1412
4. K.E. Chan, J.M. Lazarus, R. Thadhani, and R.M. Hakim Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation J Am Soc Nephrol 20 2009 2223 2233
5. J.B. Olesen, G.Y. Lip, A.L. Kamper, K. Hommel, L. Køber, D.A. Lane, J. Lindhardsen, G.H. Gislason, and C. Torp-Pedersen Stroke and bleeding in atrial fibrillation with chronic kidney disease N Engl J Med 367 2012 625 635
6. D. Menzies Systematic reviews and meta-analyses Int J Tuberc Lung Dis 15 2011 582 593
7. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement Ann Intern Med 151 2009 264 269
8. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000 Am J Kidney Dis 37 2001 S182 S238
9. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] 2011 The Cochrane Collaboration Available at: www.cochrane-handbook.org Accessed on March 2014
10. 2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 109 2013 956 960
11. V. Roldán, F. Marín, H. Fernández, S. Manzano-Fernández, P. Gallego, M. Valdés, V. Vicente, and G.Y. Lip Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding) Am J Cardiol 111 2013 1159 1164
12. A. Banerjee, L. Fauchier, P. Vourc'h, C.R. Andres, S. Taillandier, J.M. Halimi, and G.Y. Lip Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project J Am Coll Cardiol 61 2013 2079 2087
13. L. Friberg, M. Rosenqvist, and G.Y. Lip Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study Eur Heart J 33 2012 1500 1510
14. L. Friberg, L. Benson, M. Rosenqvist, and G.Y. Lip Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study BMJ 344 2012 e3522
15. J.W. Eikelboom, S.J. Connolly, P. Gao, E. Paolasso, R. De Caterina, S. Husted, M. O'Donnell, S. Yusuf, and R.G. Hart Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease J Stroke Cerebrovasc Dis 21 2012 429 435
16. S.J. Connolly, J. Eikelboom, C. Joyner, H.C. Diener, R. Hart, S. Golitsyn, G. Flaker, A. Avezum, S.H. Hohnloser, R. Diaz, M. Talajic, J. Zhu, P. Pais, A. Budaj, A. Parkhomenko, P. Jansky, P. Commerford, R.S. Tan, K.H. Sim, B.S. Lewis, W. Van Mieghem, G.Y. Lip, J.H. Kim, F. Lanas-Zanetti, A. Gonzalez-Hermosillo, A.L. Dans, M. Munawar, M. O'Donnell, J. Lawrence, G. Lewis, R. Afzal, S. Yusuf AVERROES Steering Committee and Investigators Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
17. M.J. Cha, G.C. Oh, S. Hahn, E.K. Choi, and S. Oh Thromboembolic risk evaluation in patients with atrial fibrillation using a modified CHADS(2) scoring system J Cardiovasc Electrophysiol 23 2012 155 162
18. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini, S.D. Berkowitz, K.A. Fox, R.M. Califf ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
19. 2 index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts Circulation 127 2013 224 232
20. R.G. Hart, L.A. Pearce, R.W. Asinger, and C.A. Herzog Warfarin in atrial fibrillation patients with moderate chronic kidney disease Clin J Am Soc Nephrol 6 2011 2599 2604
21. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, H.R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton, J.A. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B.J. Gersh, S. Golitsyn, S. Goto, A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis, J.L. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W. Verheugt, J. Zhu, L. Wallentin ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
22. S.H. Hohnloser, Z. Hijazi, L. Thomas, J.H. Alexander, J. Amerena, M. Hanna, M. Keltai, F. Lanas, R.D. Lopes, J. Lopez-Sendon, C.B. Granger, and L. Wallentin Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur Heart J 33 2012 2821 2830
23. H.M. Lai, W.S. Aronow, P. Kalen, S. Adapa, K. Patel, A. Goel, R. Vinnakota, S. Chugh, and R. Garrick Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin Int J Nephrol Renovasc Dis 2 2009 33 37
24. D.E. Singer, Y. Chang, L.H. Borowsky, M.C. Fang, N.K. Pomernacki, N. Udaltsova, K. Reynolds, and A.S. Go A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score J Am Heart Assoc 2 2013 e000250
25. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, L. Wallentin RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
26. Z. Hijazi, S.H. Hohnloser, J. Oldgren, U. Andersson, S.J. Connolly, J.W. Eikelboom, M.D. Ezekowitz, P.A. Reilly, A. Siegbahn, S. Yusuf, and L. Wallentin Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY trial analysis Circulation 129 2014 961 970
27. R.G. Hart, J.W. Eikelboom, A.J. Ingram, and C.A. Herzog Anticoagulants in atrial fibrillation patients with chronic kidney disease Nat Rev Nephrol 8 2012 569 578
28. R. Providência, A. Fernandes, L. Paiva, A. Faustino, S. Barra, A. Botelho, J. Trigo, J. Nascimento, and A. Leitão-Marques Decreased glomerular filtration rate and markers of left atrial stasis in patients with non-valvular atrial fibrillation Cardiology 124 2013 3 10
29. W.C. Winkelmayer, J. Liu, S. Setoguchi, and N.K. Choudhry Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation Clin J Am Soc Nephrol 6 2011 2662 2668
30. C.S. Miller, S.M. Grandi, A. Shimony, K.B. Filion, and M.J. Eisenberg Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Am J Cardiol 110 2012 453 460